3-<4-Brom-phenyl>-hydantoin | 345648-37-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 英文名称: 3-<4-Brom-phenyl>-hydantoin
• 英文别名: 3--hydantoin；3-(4-Bromophenyl)imidazolidine-2,4-dione
• CAS: 345648-37-5
• 化学式: C₉H₇BrN₂O₂
• 分子量: 255.071
• InChiKey: FPFDMHRKTCRRBC-UHFFFAOYSA-N

物化性质

• 密度：
  1.709±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  49.4
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-<4-Brom-phenyl>-hydantoin 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 potassium acetate 、 sodium carbonate 、 potassium carbonate 作用下， 以 二甲基亚砜 、 N,N-二甲基甲酰胺 为溶剂， 反应 4.0h， 生成
  参考文献：
  名称：

  The design and synthesis of novel SGLT2 inhibitors: C-glycosides with benzyltriazolopyridinone and phenylhydantoin as the aglycone moieties

  摘要：

  The sodium glucose co-transporter 2 (SGLT2) has received considerable attention in recent years as a target for the treatment of type 2 diabetes mellitus. This report describes the design, synthesis and structure-activity relationship (SAR) of C-glycosides with benzyltriazolopyridinone and phenylhydantoin as the aglycone moieties as novel SGLT2 inhibitors. Compounds 5p and 33b demonstrated high potency in inhibiting SGLT2 and high selectivity against SGLT1. The in vitro ADMET properties of these compounds will also be discussed. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2014.04.036
• 作为产物：
  描述：

  Ethyl 2-[(4-bromophenyl)carbamoylamino]acetate 以 甲醇 、 水 为溶剂， 生成 3-<4-Brom-phenyl>-hydantoin
  参考文献：
  名称：

  Mindl, Jaromir; Sterba, Vojeslav, Collection of Czechoslovak Chemical Communications, 1987, vol. 52, # 1, p. 156 - 161

  摘要：

  DOI：

文献信息

• [EN] CYCLIC UREAS AS INHIBITORS OF ROCK<br/>[FR] URÉES CYCLIQUES UTILES EN TANT QU'INHIBITEURS DE ROCK
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2016112236A1

  公开（公告）日：2016-07-14

  The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.

  本发明提供了式(I)的化合物：或其立体异构体、互变异构体或药学上可接受的盐，其中所有变量如本文所定义。这些化合物是选择性ROCK抑制剂。本发明还涉及包含这些化合物的药物组合物以及使用它们治疗心血管、平滑肌、肿瘤学、神经病理学、自身免疫、纤维化和/或炎症性疾病的方法。
• Cyclic ureas as inhibitors of rock
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US10123993B2

  公开（公告）日：2018-11-13

  The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.

  本发明提供了式(I)化合物：或其立体异构体、同系物或药学上可接受的盐，其中所有变量如本文所定义。这些化合物是选择性 ROCK 抑制剂。本发明还涉及包含这些化合物的药物组合物以及使用这些化合物治疗心血管、平滑肌、肿瘤、神经病理、自身免疫、纤维化和/或炎症性疾病的方法。
• A New Phase-Switch Method for Application in Organic Synthesis Programs Employing Immobilization through Metal-Chelated Tagging
  作者：Steven V. Ley、Alessandro Massi、Félix Rodríguez、David C. Horwell、Russell A. Lewthwaite、Martyn C. Pritchard、Alison M. Reid

  DOI：10.1002/1521-3773(20010316)40:6<1053::aid-anie10530>3.0.co;2-d

  日期：2001.3.16
• Guareschi, Chemische Berichte, 25 Ref. <1892>, 327
  作者：Guareschi

  DOI：——

  日期：——
• Structural optimization of non-nucleoside DNA methyltransferase inhibitor as anti-cancer agent
  作者：Bo Zhong、Sergei Vatolin、Nethrie D. Idippily、Rati Lama、Laila A. Alhadad、Frederic J. Reu、Bin Su

  DOI：10.1016/j.bmcl.2016.01.020

  日期：2016.2

  Inhibition of DNA methyltransferase 1 (DNMT1) can reverse the malignant behavior of cancer cells by restoring expression of aberrantly silenced genes that are required for differentiation, senescence, and apoptosis. Clinically used DNMT1 inhibitors decitabine and azacitidine inhibit their target by covalent trapping after incorporation into DNA as azacytidine analogs. These nucleoside compounds are prone to rapid enzymatic inactivation in blood, posing challenges to the development of purely epigenetic dosing schedules. Non-nucleoside compounds that suppress expression or function of DNMT1 may overcome this problem. Using a high-throughput PCR-based site specific chromatin condensation assay, we identified a compound that reactivated Cyclin-Dependent Kinase Inhibitor 2A (CDKN2A) in myeloma cells and suppressed expression of DNMT1 from a library of 5120 chemically diverse small molecules. Lead optimization was performed to generate 26 new analogs with lung cancer proliferation and DNMT1 expression as activity readout. Two of the new derivatives showed 2 fold improvement of growth inhibiting potency and also decreased DNMT1 protein levels in lung cancer cells. Published by Elsevier Ltd.